As of 2025-07-11, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -3.66 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 7.60 CAD, the upside of Eupraxia Pharmaceuticals Inc is -148.12%.
Based on its market price of 7.60 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 148.12%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.66 - -3.66 | -3.66 | -148.12% |
| DDM - Stable | (12.72) - (118.66) | (65.69) | -964.3% |
| DDM - Multi | (0.94) - (6.70) | (1.64) | -121.6% |
| Market Cap (mil) | 272.46 |
| Beta | 0.12 |
| Outstanding shares (mil) | 35.85 |
| Enterprise Value (mil) | 245.01 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.29% |
| Cost of Debt | 5.00% |
| WACC | 4.99% |